Skip to main content
. 2022 Apr 16;11(8):1361. doi: 10.3390/cells11081361

Figure 4.

Figure 4

Inhibition of Hippo pathway by VP inhibits osteosarcoma progression in Ctsk-Cre;Trp53f/f/Rb1f/f mice. (A) Schematic diagram of the time courses of VP injection and mice harvested for data analysis. (B) Representative X-ray images of femurs showing that treatment of Ctsk-Cre;Trp53f/f/Rb1f/f mice with VP 3 times per week for 12 weeks starting from 2 months. Scale bars, 1 mm. The red arrows indicate the destruction in the cortical bone. (C–F) Histomorphometric analysis of bone parameters in the femurs of Ctsk-Cre;Trp53f/f/Rb1f/f mice after treatment with 0 (control) or 100 mg/kg VP as indicated. N = 5 mice/group. (G) Representative H&E-stained images of femurs from Ctsk-Cre;Trp53f/f/Rb1f/f mice treated with 0 (control) or 100 mg/kg VP for 12 weeks. Scale bar, 1 mm. (H) Kaplan–Meier survival analysis indicating overall survival of treated with 0 (control) or 100 mg/kg VP for 12 weeks. Error bars were the means ± SEM from three independent experiments. ** p < 0.01.